Xinan Sheng - Concepedia

Author

Xinan Sheng

Also Known As

Sheng, X., X Sheng, X. N. Sheng, X. Sheng, X.N. Sheng, Xi'nan Sheng, Xi-Nan Sheng, Xi-nan Sheng, XiNan Sheng, Xiaobing Sheng

446

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Peking University Peking University Cancer Hospital Sun Yat-sen University Sun Yat-sen University Cancer Center Peking University First Hospital

About

Xinan Sheng is an author at Peking University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	43	1.4K
2	Health Sciences	3	3	56
3	Engineering	1	1	15
4	Natural Sciences	1	1	20
5	Biochemistry	1	1	11

Xinan Sheng

112

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification Jun Guo, Lu Si, Yan Kong, Journal of Clinical Oncology	2011	673
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases Zhihong Chi, Siming Li, Xinan Sheng, BMC Cancer	2011	395
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Xinan Sheng, Xieqiao Yan, Lin Wang, Clinical Cancer Research	2020	266
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort Lu Si, Yan Kong, Xiaowei Xu, European Journal of Cancer Chinese Melanoma PatientsSkin CancerMedicineMelanomaGenetic Epidemiology	2011	264
Large-Scale Analysis of <i>KIT</i> Aberrations in Chinese Patients with Melanoma Yan Kong, Lu Si, Yanyan Zhu, Clinical Cancer Research	2011	251
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Bin Lian, Lu Si, Chuanliang Cui, Clinical Cancer Research	2013	193
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients Bixia Tang, Xieqiao Yan, Xinan Sheng, Journal of Hematology & Oncology	2019	185
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients Jiayi Yu, Xiaowen Wu, Junya Yan, Journal of Hematology & Oncology	2018	183
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial Xinan Sheng, Xieqiao Yan, Zhihong Chi, Journal of Clinical Oncology	2019	165
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors Yingying Xu, Yakun Wang, Jifang Gong, Gastric Cancer	2021	140

Page 1